Evidence map›Paper›PMID 41853492›Full record

ArticleFrontiers in pharmacology2026

Bioequivalence study of testosterone undecanoate soft capsules in healthy postmenopausal women under fed conditions: a single-center, four-period, repeated crossover trial.

Nanxing Li, Fengjia Zhu, Zhongyuan Zhao, Shilong Zhu, Jinlian Wu, Xu Zuo, Jinjin Shi, Xiuhui Qian, Xiaoping Zhang, Yuanyuan Hu and 3 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nanxing Li *Research and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Fengjia Zhu *Research and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Zhongyuan ZhaoResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Shilong ZhuSchool of Engineering, China Pharmaceutical University, Nanjing, Jiangsu, China.
Jinlian WuResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Xu ZuoDepartment of Clinical Pharmacology, Xinxiang Central Hospital, Xinxiang, Henan, China.
Jinjin ShiDepartment of Clinical Pharmacology, Xinxiang Central Hospital, Xinxiang, Henan, China.
Xiuhui QianResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Xiaoping ZhangResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Yuanyuan HuShanghai Xihua Scientific Co., Ltd., Shanghai, China.
Yueran LvResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Jing ChenResearch and Development Center, Zhejiang Medicine Co., Ltd., Shaoxing, Zhejiang, China.
Tiandong ZhangDepartment of Clinical Pharmacology, Xinxiang Central Hospital, Xinxiang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to systematically evaluate the pharmacokinetics, bioequivalence, and safety of a single postprandial oral dose of testosterone undecanoate (TU) and its originator drug Andriol Testocaps Methods: A randomized, open-label, two-treatment, four-period, single-center, single-dose crossover clinical trial was conducted at Xinxiang Central Hospital. Participants received single oral doses of 40 mg TU or Andriol Testocaps Results: The average adjusted geometric mean ratios (GMR) (90% CI) for the primary PK parameters C Conclusion: TU demonstrated bioequivalence to Andriol Testocaps

Indexed as

bioequivalenceChinese healthy participantspharmacokineticssafetytestosterone undecanoate

Identifiers

PMID41853492
PMCPMC12992283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.